{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:51:53Z","timestamp":1777899113391,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.carrev.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T02:31:02Z","timestamp":1642127462000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of 2-Year Mortality With Use of Drug-Coated Devices in Femoropopliteal Disease: A Real-World Experience From the Bronx, New York"],"prefix":"10.1016","volume":"41","author":[{"given":"Israel","family":"Safiriyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Gumber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Palaiodimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetal V.","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aksim","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Karamanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2022.01.009_bb0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2022.01.009_bb0010","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00270-014-0876-3","article-title":"Standards of practice for superficial femoral and popliteal artery angioplasty and stenting","volume":"37","author":"Katsanos","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0015","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2022.01.009_bb0020","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.jvs.2011.09.001","volume":"54","author":"Rooke","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2022.01.009_bb0025","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with Lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.CIR.96.2.636","article-title":"Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery","volume":"96","author":"Axel","year":"1997","journal-title":"Circulation."},{"key":"10.1016\/j.carrev.2022.01.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2016.10.089","article-title":"Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty","volume":"65","author":"Candy","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2022.01.009_bb0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ahj.2014.11.016","article-title":"Drug-coated balloons to improve femoropopliteal artery patency: rationale and design of the LEVANT 2 trial","volume":"169","author":"Jaff","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2022.01.009_bb0045","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.ijcard.2013.06.081","article-title":"Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison","volume":"168","author":"Fusaro","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0050","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jcin.2016.08.036","article-title":"Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial","volume":"9","author":"Salisbury","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2022.01.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2022.01.009_bb0060","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","article-title":"Mortality and paclitaxel-coated devices: an individual patient data meta-analysis","volume":"141","author":"Rocha-Singh","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.carrev.2022.01.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012524","article-title":"Is there a real association between paclitaxel devices and mortality? Time to pause and re-evaluate what we know about this statistical finding","volume":"8","author":"Shishehbor","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2022.01.009_bb0070","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.jcin.2019.08.025","article-title":"Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease","volume":"12","author":"Ouriel","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2022.01.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018149","article-title":"Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: insights from the veterans health administration","volume":"10","author":"Gutierrez","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2022.01.009_bb0080","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.jacc.2019.01.013","article-title":"Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon","volume":"73","author":"Schneider","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","article-title":"Association of survival with femoropopliteal artery revascularization with drug-coated devices","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0090","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jvs.2019.10.100","article-title":"Paclitaxel-coated peripheral artery devices are not associated with increased mortality","volume":"72","author":"Kumins","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2022.01.009_bb0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"10.1016\/j.carrev.2022.01.009_bb0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.carrev.2022.01.009_bb0105","article-title":"Optimal caliper width for propensity score matching of three treatment groups: a Monte Carlo study","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.carrev.2022.01.009_bb0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1467-985X.2007.00527.x","article-title":"Misunderstandings between experimentalists and observationalists about causal inference","volume":"171","author":"Imai","year":"2008","journal-title":"J R Stat Soc A Stat Soc"},{"key":"10.1016\/j.carrev.2022.01.009_bb0115","series-title":"Sianesi. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing","author":"Edwin","year":"2003"},{"key":"10.1016\/j.carrev.2022.01.009_bb0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jvs.2014.01.041","article-title":"Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery","volume":"59","author":"Katsanos","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2022.01.009_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00270-019-02324-4","article-title":"Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices","volume":"43","author":"Dake","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.carrev.2022.01.009_bb0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1526602819898804","article-title":"Paclitaxel-coated balloon for the treatment of infrainguinal disease: 12-month outcomes in the all-comers cohort of BIOLUX P-III global registry","volume":"27","author":"Tepe","year":"2020","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.carrev.2022.01.009_bb0135","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","article-title":"Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial","volume":"5","author":"Werk","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2022.01.009_bb0145","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2022.01.009_bb0150","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jcin.2020.04.050","article-title":"Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in the real world","volume":"13","author":"Bohme","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2022.01.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002938","article-title":"Critical limb ischemia: current trends and future directions","volume":"5","author":"Teraa","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838922000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838922000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:24:09Z","timestamp":1761560649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838922000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":30,"alternative-id":["S1553838922000094"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2022.01.009","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of 2-Year Mortality With Use of Drug-Coated Devices in Femoropopliteal Disease: A Real-World Experience From the Bronx, New York","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}